Eliane Schutte is Xeltis Chief Executive Officer since 2018. Under her leadership, the company expanded its strategy to cover valve and vascular applications and closed a €10.5 million Series D financing round. She initially joined Xeltis in 2015 as Chief Development Officer, leading its clinical trial program, product development strategy and regulatory.
Schutte has extensive expertise in global product development and regulatory affairs in medical devices, with over 20 years of experience in the biotech industry. Prior to Xeltis, she was Vice President for global product development in peri-operative care at The Medicines Company. She was previously chief development officer at Profibrix, a Dutch-US biotech start-up acquired by The Medicines Company and vice president for regulatory affairs and EU operations at IsoTis Orthobiologics.